GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

Search

Proto Labs

Atidarymo kaina

SektoriusPramonės sektorius

43.89 0.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

42.58

Max

43.97

Pagrindiniai rodikliai

By Trading Economics

Pajamos

4M

3.6M

Pardavimai

4.5M

126M

P/E

Sektoriaus vid.

66.067

42.612

Pelno marža

2.852

Darbuotojai

2,357

EBITDA

-8.4M

4.5M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+15.77% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

101M

942M

Ankstesnė atidarymo kaina

43.62

Ankstesnė uždarymo kaina

43.89

Naujienos nuotaikos

By Acuity

50%

50%

209 / 461 reitingas Industrials

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Proto Labs Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-04 21:42; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-08-04 19:15; UTC

Pagrindinės rinkos jėgos

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025-08-04 23:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-04 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Fed Stimulus Hopes

2025-08-04 23:28; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-08-04 23:28; UTC

Rinkos pokalbiai

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025-08-04 21:30; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 21:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025-08-04 21:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025-08-04 20:25; UTC

Rinkos pokalbiai

India Hits Back Over Russian Oil Purchases -- Market Talk

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss $938M >RIG

2025-08-04 20:25; UTC

Uždarbis

Transocean 2Q Loss/Shr $1.06 >RIG

2025-08-04 20:18; UTC

Uždarbis

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:09; UTC

Uždarbis

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025-08-04 20:06; UTC

Uždarbis

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-08-04 19:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-08-04 19:28; UTC

Rinkos pokalbiai

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025-08-04 19:07; UTC

Rinkos pokalbiai

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025-08-04 18:27; UTC

Rinkos pokalbiai

Gold Climbs on Rate Cut Speculation -- Market Talk

Akcijų palyginimas

Kainos pokytis

Proto Labs Prognozė

Kainos tikslas

By TipRanks

15.77% į viršų

12 mėnesių prognozė

Vidutinis 50 USD  15.77%

Aukščiausias 54 USD

Žemiausias 45 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Proto Labs kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

3

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

35.09 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

209 / 461 reitingas Pramonės sektorius

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Proto Labs

Proto Labs, Inc., together with its subsidiaries, operates as a digital manufacturer of custom parts in the United States and Europe. The company offers injection molding; computer numerical control machining; three-dimensional printing; and sheet metal fabrication products. It serves developers and engineers, who use 3D computer-aided design software to design products across a range of end-markets. Proto Labs, Inc. was incorporated in 1999 and is headquartered in Maple Plain, Minnesota.